Development of a European Organization for Research and Treatment of Cancer questionnaire module to assess the quality of life of ovarian cancer patients in clinical trials: a progress report
Development of a European Organization for Research and Treatment of Cancer questionnaire module to assess the quality of life of ovarian cancer patients in clinical trials: a progress report
复制标题
DOI：
10.1016/s0959-8049(00)00369-5
复制
发表时间：
2001-01-01
影响因子：
8.4
通讯作者：
Gould, A
中科院分区：
文献类型：
--
作者：
Cull, A;Howat, S;Gould, A
根据欧洲癌症研究和治疗组织（EORTC）发布的指南，开发了一份问卷，以补充EORTC生活质量量表核心30（QLQ-C30），以评估在临床试验中接受治疗的卵巢癌女性的生活质量（QL）。暂定28项模块，OV 28。评估腹部症状;周围神经病变;其他化疗副作用;激素症状;身体形象;对疾病和治疗的态度。和性功能该模块的前24个项目（不包括性功能）被纳入英国多中心试验（SCOTROC）。试验数据用于初步的缩放分析。查明了两个问题项目。当这些与“其他化疗副作用”一起作为单项沿着处理时，该仪器显示出优异的标度特性。平均量表评分区分试验患者化疗前和化疗中。这是一个很有前途的工具，用于评估卵巢癌妇女的QL。EORTC国际研究（方案15982）正在进行中，以更全面地评估OV 28的心理测量特性。(C)2001爱思唯尔科技有限公司版权所有。
A questionnaire was developed, according to the European Organization fur Research and Treatment of Cancer (EORTC) published guidelines, to supplement the EORTC quality of life questionnaire-core 30 (QLQ-C30) to assess the quality of life (QL) of women with ovarian cancer treated in clinical trials. The provisional 28-item module, OV28. assesses abdominal symptoms; peripheral neuropathy; other chemotherapy side-effects: hormonal symptoms: body image: attitude to disease and treatment. and sexual functioning. The first 24 items of the module (excluding sexual functioning) were included in a UK multicentre trial (SCOTROC). The trial data were used for preliminary scaling analysis. Two problematic items were identified. When these were treated as single items along with the 'other chemotherapy side-effects' the instrument showed excellent scale properties. Mean scale scores discriminated between trial patients pre- and on chemotherapy. This is a promising tool for assessing the QL of women with ovarian cancer. The EORTC international held study (Protocol 15982) to assess more fully the psychometric properties of the OV28 is well underway. (C) 2001 Elsevier Science Ltd. All rights reserved.